Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CANTATA-M
- Sponsors Janssen Research & Development
- 08 Jul 2022 Results of post-hoc analysis of five studies (NCT01081834, NCT01106677, NCT00968812, NCT01032629 & NCT01989754) assessing efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method, published in the Diabetologia.
- 15 Sep 2017 Results of a post-hoc analysis assessing the effect of Canagliflozin on liver function tests and liver fibrosis in patients from four phase III trials (CANTATA-M, CANTATA-MSU, CANTATA-D and CANTATA-MP) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 01 Apr 2017 Pooled results of a post hoc analysis assessing the effects of canagliflozin on serum magnesium in hypomagnesemic patients from four placebo-controlled studies (CANTATA-MP, CANTATA-M, CANTATA-MSU, and CANTATA-D; n=2313) published in the Diabetes Therapy